Yosef Landesman, PhD

Senior Vice President, Research and Translational Medicine

Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. In this role, he leads Preclinical and Clinical Research, Karyopharm’s Expanded Access Program, as well as the departments of Translational Development, Preclinical Pharmacology, Bioinformatics, and Clinical and Preclinical Publications. During his time at Karyopharm, Dr. Landesman has expanded on his broad experience in oncology at virtually every stage of drug development: from early discovery through clinical trial and approval. He led the preclinical development of XPOVIO® (selinexor) and initiated discovery of the Pak4/NAMPT dual inhibitor KPT-9274, currently in a Phase 1 clinical trial.

Prior to joining Karyopharm, Dr. Landesman worked at Alnylam Pharmaceuticals where he had a critical role in the establishment of the “RNAi Lead Development” department. In this multi-faceted position, he developed and optimized an efficient and simple method to quantify the delivery of siRNA and significantly contributed to the development of ONPATTRO® (patisiran). In addition, he was instrumental in a technology transfer agreement between Alnylam and Takeda Pharmaceuticals. He began his career as a scientist at GPC Biotech where he developed CDK small drug inhibitors and had a leadership role in the collaboration between GPC Biotech and the ALTANA Research Institute.

Dr. Landesman received his Bachelor and Master of Science degrees in Genetics from the Hebrew University of Jerusalem. He went on to earn his Doctor of Philosophy in Molecular Genetics and Virology from the Weizmann Institute of Science and completed his postdoctoral training at Harvard Medical School where he was also a faculty member of the Neurology Department.